HQL News and Press, TeklaLife Sciences Investors From 08/13/21

In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...

Closed-ends funds as a whole have become quite stretched in value, this isn't any different for HQH. HQH holds an overweight exposure to biotech in the healthcare space - as the biotech space has been cooling down so has HQH. If you are a current shareholder, I believe it still ma...

As an income investor, the 7.8% yield is quite attractive to me if HQL can support it. I continue my series on CEFs looking beyond the yield. The distribution is fully covered and I expect the NAV to continue its upward trend. Between an increasing NAV, and the resultant distr...

20 out of 23 CEF sectors positive on price and 21 out of 23 sectors positive on NAV last week. GAB rights offering is now live. IGA/IGD/IDE tender results were pleasing, DEX tender coming up. DSE to merge into an open-ended fund soon. Portfolio holdings: distribution boost...

From a consumer perspective, the consumer is actually now demanding a focus on environmental, social, governance factors. If public expectations for inflation do rise, that is going to be a change from years past. There’s going to be an opportunity to make medical progress ...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

Tekla Life Sciences (HQL) declares $0.41/share quarterly dividend, -4.7% decrease from prior dividend of $0.43.Forward yield 8.32%Payable June 30; for shareholders of record May 28; ex-div May 27.See HQL Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Te...

Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure. Today we explore the differences and the similarities of the funds. For further details see: Tekla ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

In January 2020, only 0.24% of total medical claims in the U.S. were telemedicine-related. One year later, they totaled 7%. It took 15 years for e-commerce penetration to rise from less than 1% to over 7%. The pandemic helped telemedicine do it in one. Population-wide immunity to ...